SEARCH

SEARCH BY CITATION

References

  • Alnaes R. and Kristiansen J. (1963) [Desmethylimipramine (Pertofran) in the treatment of depressions. A clinical and psychodynamic appraisal]. Nord. Psykiatr. Tidsskr. 17, 425436.
  • Bosque P. J. and Prusiner S. B. (2000) Cultured cell sublines highly susceptible to prion infection. J. Virol. 74, 43774386.
  • Butler J. D., Blanchette-Mackie J., Goldin E. et al. (1992) Progesterone blocks cholesterol translocation from lysosomes. J. Biol. Chem. 267, 23 79723 805.
  • Collinge J., Sidle K. C. L., Meads J., Ironside J. and Hill A. F. (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383, 685690.
  • Collins S. J., Lewis V., Brazier M., Hill A. F., Fletcher A. and Masters C. L. (2002) Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol. 52, 503506.
  • Cordy J. M., Hussain I., Dingwall C., Hooper N. M. and Turner A. J. (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl Acad. Sci. U S A 100, 11 73511 740.
  • Doh-ura K., Iwaki T. and Caughey B. (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. 74, 48944897.
  • Doh-ura K., Ishikawa K., Murakami-Kubo I., Sasaki K., Mohri S., Race R. and Iwaki T. (2004) Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol. 78, 49995006.
  • Ehehalt R., Keller P., Haass C., Thiele C. and Simons K. (2003) Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113123.
  • Fassbender K., Simons M., Bergmann C. et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. U S A 98, 58565861.
  • Giles J. (2004) Tissue survey raises spectre of ‘second wave’ of vCJD. Nature 429, 331.
  • Griffiths G., Lucocq J. M. and Mayhew T. M. (2001) Electron microscopy applications for quantitative cellular microbiology. Cell Microbiol. 3, 659668.
  • Hilton D. A., Ghani A. C., Conyers L., Edwards P., McCardle L., Ritchie D., Penney M., Hegazy D. and Ironside J. W. (2004) Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J. Pathol. 203, 733739.
  • Kaneko K., Vey M., Scott M., Pilkuhn S., Cohen F. E. and Prusiner S. B. (1997) COOH-terminal sequence of the cellular prion protein directs subcellular trafficking and controls conversion into the scrapie isoform. Proc. Natl. Acad. Sci. U S A 94, 23332338.
  • Korth C., Streit P. and Oesch B. (1999) Monoclonal antibodies specific for the native, disease-associated isoform of the prion protein. Methods Enzymol. 309, 102112.
  • Korth C., May B. C. H., Cohen F. E. and Prusiner S. B. (2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. U S A 98, 98369841.
  • Kuhn R. (1958) The treatment of depressive states with G 22355 (imipramine hydrochloride). Am. J. Psychiatry 115, 459464.
  • Lajoie P., Guay G., Dennis J. W. and Nabi I. R. (2005) The lipid composition of autophagic vacuoles regulates expression of multilamellar bodies. J. Cell Sci. 118, 19912003.
  • Liou W., Geuze H. J. and Slot J. W. (1996) Improving structural integrity of cryosections for immunogold labeling. Histochem. Cell Biol. 106, 4158.
  • Liscum L. and Underwood K. W. (1995) Intracellular cholesterol transport and compartmentation. J. Biol. Chem. 270, 15 44315 446.
  • Llewelyn C. A., Hewitt P. E., Knight R. S., Amar K., Cousens S., Mackenzie J. and Will R. G. (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363, 417421.
  • Lullmann H., Lullmann-Rauch R. and Wassermann O. (1978) Lipidosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. 27, 11031108.
  • Marella M., Lehmann S., Grassi J. and Chabry J. (2002) Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J. Biol. Chem. 277, 25 45725 464.
  • May B. C., Fafarman A. T., Hong S. B., Rogers M., Deady L. W., Prusiner S. B. and Cohen F. E. (2003) Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl Acad. Sci. U S A 100, 34163421.
  • Mobius W., Van Donselaar E., Ohno-Iwashita Y., Shimada Y., Heijnen H. F., Slot J. W. and Geuze H. J. (2003) Recycling compartments and the internal vesicles of multivesicular bodies harbor most of the cholesterol found in the endocytic pathway. Traffic 4, 222231.
  • Nakajima M., Yamada T., Kusuhara T., Furukawa H., Takahashi M., Yamauchi A. and Kataoka Y. (2004) Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 17, 158163.
  • Palmeri S., Battisti C., Malandrini A. and Federico A. (1995) Amiodarone induced lipidosis similar to Niemann-Pick C disease. Biochemical and morphological study. Life Sci. 57, 19631971.
  • Patterson M. C., Vanier M. T., Suzuki S., Morris J. A., Carstea E., Neufeld E. B., Blanchette-Mackie J. E. and Pentchev P. G. (2001) Niemann–Pick disease type C: a lipid trafficking disorder, in The Metabolic and Molecular Bases of Inherited Disease, 8th edn, Vol. III (Scriver, C. R., Beaudet, A. L., Sly, W. S. and Valle, D., eds), pp. 36113633. McGraw-Hill, New York.
  • Peden A. H., Head M. W., Ritchie D. L., Bell J. E. and Ironside J. W. (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364, 527529.
  • Peters P. J., Bos E. and Griekspoor A. (2006) Cryo-immunogold electron microscopy. Curr. Protocols Cell Biol. 4.7.14.7.19. John Wiley & Sons, Hoboken, New Jersey.
  • Peters P. J., Mironov A. Jr, Peretz D. et al. (2003) Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J. Cell Biol. 162, 703717.
  • Prusiner S. B. (1998) Prions. Proc. Natl. Acad. Sci. U S A 95, 13 36313 383.
  • Rodriguez-Lafrasse C., Rousson R., Bonnet J., Pentchev P. G., Louisot P. and Vanier M. T. (1990) Abnormal cholesterol metabolism in imipramine-treated fibroblast cultures. Similarities with Niemann-Pick type C disease. Biochim. Biophys. Acta 1043, 123128.
  • Ryou C., Lessard P., Freyman Y. et al. (2004) In vivo efficacy of quinacrine in animal models of prion disease. Paris International Neuroprion Meeting, p. 169. Paris.
  • Saheki A., Terasaki T., Tamai I. and Tsuji A. (1994) In vivo and in vitro blood–brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CaA) reductase inhibitors. Pharm. Res. 11, 305311.
  • Sanchez C. and Hyttel J. (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol. Neurobiol. 19, 467489.
  • Schuck S., Honsho M., Ekroos K., Shevchenko A. and Simons K. (2003) Resistance of cell membranes to different detergents. Proc. Natl Acad. Sci. U S A 100, 57955800.
  • Scott M. R., Will R., Ironside J., Nguyen H.-O. B., Tremblay P., DeArmond S. J. and Prusiner S. B. (1999) Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc. Natl. Acad. Sci. U S A 96, 15 13715 142.
  • Sexton R. C., Panini S. R., Azran F. and Rudney H. (1983) Effects of 3 beta-[2-(diethylamino) ethoxy]androst-5-en-17-one on the synthesis of cholesterol and ubiquinone in rat intestinal epithelial cell cultures. Biochemistry 22, 56875692.
  • Simons K. and Ikonen E. (1997) Functional rafts in cell membranes. Nature 387, 569572.
  • Simons M., Schwarzler F., Lutjohann D., Von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T. and Schulz J. B. (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52, 346350.
  • Taraboulos A., Scott M., Semenov A., Avrahami D., Laszlo L. and Prusiner S. B. (1995) Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibits formation of the scrapie isoform. J. Cell Biol. 129, 121132.
  • Vey M., Pilkuhn S., Wille H., Nixon R., DeArmond S. J., Smart E. J., Anderson R. G., Taraboulos A. and Prusiner S. B. (1996) Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc. Natl. Acad. Sci. U S A 93, 14 94514 949.
  • Vogtherr M., Grimme S., Elshorst B., Jacobs D. M., Fiebig K., Griesinger C. and Zahn R. (2003) Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J. Med. Chem. 46, 35633564.
  • Will R. G., Ironside J. W., Zeidler M., Cousens S. N., Estibeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A. and Smith P. G. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921925.
  • Yung L., Huang Y., Lessard P., Legname G., Lin E. T., Baldwin M. A., Prusiner S. B., Ryou C. and Guglielmo B. J. (2004) Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect. Dis. 4, 53.
  • Zhang J., Spring H. and Schwab M. (2001) Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett. 171, 153164.
  • Zipes D. P. and Troup P. J. (1978) New antiarrhythmic agents: amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil. Am. J. Cardiol. 41, 10051024.